LifeMD, Inc.

LFMD

US53216B1044

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
9.61 ^USD	-0.52%		-3.90%	+15.92%

Mar. 12	Craig-Hallum Adjusts LifeMD's Price Target to $15 From $10, Maintains Buy Rating	MT
Mar. 12	Cantor Fitzgerald Adjusts Price Target on LifeMD to $11 From $9, Maintains Overweight Rating	MT

Mark McLaughlin entered into a definitive agreement to acquire Yeast Beta Glucan manufacturing business from ImmuDyne, Inc. for $0.85 million.

January 29, 2018

Mark McLaughlin entered into a definitive agreement to acquire Yeast Beta Glucan manufacturing business from ImmuDyne, Inc. (OTCPK:IMMD) for $0.85 million on January 29, 2018.

Latest news about LifeMD, Inc.

Craig-Hallum Adjusts LifeMD's Price Target to $15 From $10, Maintains Buy Rating	Mar. 12	MT
Cantor Fitzgerald Adjusts Price Target on LifeMD to $11 From $9, Maintains Overweight Rating	Mar. 12	MT
B. Riley Securities Lifts LifeMD's PT to $12 From $11 After 'Strong' Q4 2023 Results, Maintains Buy Rating	Mar. 12	MT
LifeMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
Transcript : LifeMD, Inc., Q4 2023 Earnings Call, Mar 11, 2024	Mar. 11
Earnings Flash (LFMD) LIFEMD Reports Q4 Revenue $44.9M, vs. Street Est of $40.5M	Mar. 11	MT
Earnings Flash (LFMD) LIFEMD Posts Q4 EPS $0.15, vs. Street Est of $0.03	Mar. 11	MT
LifeMD, Inc. Provides Earnings Guidance for the First Quarter of 2024 and Revises Earnings Guidance for the Full Year of 2024	Mar. 11	CI
HC Wainwright Adjusts LifeMD Price Target to $12 From $10, Maintains Buy Rating	Jan. 11	MT
LifeMD Provides 2024 Financial Guidance	Jan. 08	RE
LifeMD, Inc. Provides Earnings Guidance for the Fiscal Year 2024	Jan. 08	CI
WeightWatchers Stock Drops 12% After Eli Lilly Launches DTC Weight-Loss Drug Service	Jan. 04	DJ
Medifast, LifeMD Collaborate to Offer Weight Management Solution; Medifast Scraps Quarterly Dividend	Dec. 13	MT
Transcript : LifeMD, Inc., Medifast, Inc. - Special Call	Dec. 13
Medifast Initiates Business Transformation by Entering the Medically Supported Weight Loss Market through Collaboration with LifeMD, Inc	Dec. 13	CI
LifeMD, Inc. announced that it has received $10.000001 million in funding from Jason Pharmaceuticals, Inc.	Dec. 11	CI
LifeMD, Inc. announced that it expects to receive $10.000001 million in funding from Jason Pharmaceuticals, Inc.	Dec. 10	CI
Lifemd, Inc. Announces Resignation of Bertrand Velge from His Position as Member of the Board of Directors	Nov. 14	CI
Cantor Fitzgerald Adjusts LifeMD's Price Target to $9 From $8, Maintains Overweight Rating	Nov. 14	MT
HC Wainwright Adjusts Price Target on LifeMD to $10 From $9, Maintains Buy Rating	Nov. 09	MT
B. Riley Raises LifeMD's Price Target to $11 From $7 After Q3 Topline Beat, Maintains Buy Rating	Nov. 09	MT
LifeMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Transcript : LifeMD, Inc., Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Earnings Flash (LFMD) LIFEMD Posts Q3 Revenue $38.6M, vs. Street Est of $38.2M	Nov. 08	MT
Earnings Flash (LFMD) LIFEMD Reports Q3 EPS $0.08, vs. Street Est of $0.03	Nov. 08	MT

LifeMD, Inc. is a direct-to-patient telehealth company, which provides comprehensive virtual and in-home healthcare. The Company operates through two segments: Telehealth and WorkSimpli. Telehealth segment is engaged in telehealth platform, which integrates a clinician-centric electronic medical record (EMR) system, algorithms for case-load balancing and scheduling, customer relationship management functionality, asynchronous communication, secure synchronous, cloud pharmacy and more. Its technology platform, combined with its 50-state affiliated provider network, enables the management of virtual treatment offerings across various health conditions, including, dermatology, urgent and primary care, chronic care management, dermatology, chronic care management and other. Its WorkSimpli segment offers workplace and document services. This segment offers PDFSimpli an online software as a service platform that allows users to create, edit, convert, sign and share PDF documents.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for LifeMD, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.61 USD

Average target price

12.6 USD

Spread / Average Target

+31.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Software & Technology Services

	1st Jan change	Capi.
LIFEMD, INC.	+15.92%	388M
VEEVA SYSTEMS INC.	+4.73%	32.54B
PRO MEDICUS LIMITED	+6.44%	7.18B
SECTRA AB	+14.39%	3.73B
EVOLENT HEALTH, INC.	-8.27%	3.45B
OMNICELL, INC.	-28.57%	1.23B
LUNIT INC.	-34.80%	1.11B
SIMULATIONS PLUS, INC.	+2.12%	913M
B-SOFT CO.,LTD.	-41.53%	817M
VERADIGM INC.	-28.41%	808M

Medical Software & Technology Services

LifeMD, Inc.

Equities

LFMD

US53216B1044

Advanced Medical Equipment & Technology

Mark McLaughlin entered into a definitive agreement to acquire Yeast Beta Glucan manufacturing business from ImmuDyne, Inc. for $0.85 million.

Latest news about LifeMD, Inc.

Chart LifeMD, Inc.

Company Profile

Income Statement Evolution

Ratings for LifeMD, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Medical Software & Technology Services